FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to clinical laboratory diagnostics, and can be used for prediction of the disease outcome in coronavirus infection caused by SARS-CoV-2 virus. Blood plasma is analysed for content of platelet-derived microparticles CD41+ by flow cytometry. If the content in plasma is not more than 3.3% of these particles, a favourable outcome of the disease is predicted. If the content in the plasma is more than 3.3 % of these particles, an unfavourable course and outcome of the disease are predicted.
EFFECT: method enables predicting the outcome of the disease in coronavirus infection caused by the SARS-CoV-2 virus by determining the CD41+ microparticles content in the blood plasma.
1 cl, 2 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTING OUTCOMES OF COVID-19 | 2023 |
|
RU2830374C1 |
| METHOD FOR DIAGNOSING MACROPHAGE ACTIVATION SYNDROME IN A NEW CORONAVIRUS INFECTION CAUSED BY THE SARS VIRUS - COV-2 | 2022 |
|
RU2778779C1 |
| METHOD FOR PREDICTION OF LETHAL OUTCOME IN PATIENTS WITH CYTOKINE STORM ASSOCIATED WITH COVID-19 | 2022 |
|
RU2825710C2 |
| METHOD FOR PREDICTING RISK OF DEATH IN HOSPITALIZED PATIENTS WITH COVID-19 RECEIVING RENAL REPLACEMENT THERAPY WITH PROGRAMMED HAEMODIALYSIS FOR STAGE 5 CHRONIC KIDNEY DISEASE | 2024 |
|
RU2829424C1 |
| METHOD FOR PREDICTION OF OUTCOME OF ACUTE DISEASE CAUSED BY NEW CORONAVIRUS INFECTION COVID-19 | 2021 |
|
RU2766347C1 |
| METHOD FOR DETERMINING THE DEGREE OF RISK OF DEVELOPING CARDIOVASCULAR COMPLICATIONS IN COVID-19 | 2021 |
|
RU2768575C1 |
| METHOD OF PREDICTING THE RISK OF DEATH FROM COVID-19 IN YOUNG PATIENTS | 2023 |
|
RU2803002C1 |
| METHOD OF PREDICTING THE RISK OF DEATH IN PATIENTS WITH COVID-19 | 2023 |
|
RU2812749C1 |
| METHOD FOR PREDICTION OF LETHAL OUTCOME IN SARS-CoV-2-ASSOCIATED PNEUMONIA | 2023 |
|
RU2825705C1 |
| METHOD OF PREDICTING THE RISK OF DEVELOPING CHRONIC HEART FAILURE IN PATIENTS WHO HAVE HAD A NEW CORONAVIRUS INFECTION COVID-19 | 2023 |
|
RU2805601C1 |
